QR Code

Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma

BackgroundBlood eosinophil count is usually employed as a predictive and response biomarker for mepolizumab treatment. However, its decrease is not always associated with an improvement in asthma symptoms. The aim of this work is to study the effect of mepolizumab in the activation status and functi...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Pablo Miguéns-Suárez, Laura Martelo-Vidal, Sara Vázquez-Mera, Marina Blanco-Aparicio, Uxío Calvo-Álvarez, Coral González-Fernández, Mar Mosteiro-Añón, Dolores Corbacho-Abelaira, Tamara Hermida-Valverde, Christian Calvo-Henríquez, Juan J. Nieto-Fontarigo, Francisco J. Salgado, Francisco J. González-Barcala
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Frontiers Media S.A. 2025-11-01
Rangatū:Frontiers in Immunology
Ngā marau:
anti-IL-5 mAb
biologic
eosinophil activation
eosinophil subsets
IL-5
severe asthma
Urunga tuihono:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1654111/full
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite